Social Media listening on Steglatro: Research and Study on Social Media Channels

PUNE, INDIA - Apr 16, 2018 - Research Study Background

On 19th December 2017, FDA approves another robust anti-diabetic drug adjunct with diet and exercise name Steglatro (ertugliflozin) oral sodium-glucose cotransporter 2 (SGLT2) inhibitor by Merck. The drug will compete with the SGLT2 inhibitors leading drug in the market Invokana (Johnson & Johnson’s), Farxiga (AstraZeneca Plc’s) and Jardiance (Eli Lilly and Boehringer Ingelheim’s).

The approval was on the basis of (VERTIS MET, VERTIS SITA) were drug has succesfully met end -point by improving the A1c or blood glucose level in patients with daibetes. Merck and Pfizer has decided to launch its robust diabetic medicine in early 2018 to help patients with diabetes

1.        Study was conducted to understand initial social media reaction on Steglatro where total 240 online posts were analysed by our subject matter experts.

2.       Study monitoring period was considered from 1st December - 31th December 2017.

Findings:

1.       Majority of HCPs, Journalists, Pharmacist and Other Individual spreading information on Steglatro (ertugliflozin) across social media channels related to US FDA approval in which Twitter followed by Mainstream Media and blogs have maximum volume of conversations.

2.       Optimistic conversation on Steglatro were related to its efficacy and Merck Stocks and Share market which says- “$MRK (+0.1% pre) FDA OKs Merck's ertugliflozin/sitagliptin for T2D -SA”  while Counteractive conversations were observed related to its adverse side effects-”Density Lipoprotein Cholesterol (LDL-C) Dose-related increases in LDL -C can occur with ertugliflozin”

Get More Information : http://www.socioinsider.com/Social-media-monitoring-Steglatro

Sentiment Analysis on Eskata Drug Approval

Positive:  People are positive around newly approved robust anti-diabetic drug Steglatro- “Efficacy and Safety When Adding Ertugliflozin to Metformin and Sitagliptin: The mean reduction of weight in the treatment group was significant, consistent with SGLT-2 mild benefit of inducing weight loss”- Other Individual (ANNIEMSULLIVAN)

Negative:  There are few conversations around Merck and Pfizer shares fall down- “$MRK FDA OKs Merck's ertugliflozin for T2D the FDA approves Merck's (MRK -0.2%) Steglujan (ertugliflozin) for glycemic control in type 2 diabetics”- Other Individual (7LADYQ)

Neutral:  Majority of individuals and HCPs and Patients neutral about the approval, and found sharing the information on social media platform- “@US_FDA approves Ertugliflozin for type 2 #diabetes “- HCP (SNAMENDYS)